Company: SMNR
Filing Date: 2025-10-21
Form Type: S-1
Source: 0001193125-25-245178
Chunk: 368

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-10-21
Form: S-1
Chunk 368
---
 share:                 |     |                                     |            |   |     |                       |            |   |     |                                     |            |   |     |                       |            |   |
| Numerators:                                                    |     |                                     |            |   |     |                       |            |   |     |                                     |            |   |     |                       |            |   |
| Allocation of net loss including accretion of temporary equity |     | $                                   | (1,098,113 | ) |     | $                     | (1,037,563 | ) |     | $                                   | (3,720,244 | ) |     | $                     | (1,290,491 | ) |
| Accretion of temporary equity to redemption value              |     |                                     |  1,968,370 |   |     |                       |          — |   |     |                                     |  5,643,271 |   |     |                       |          — |   |
| Allocation of net income/(loss)                                |     | $                                   |    870,257 |   |     | $                     | (1,037,563 | ) |     | $                                   |  1,923,027 |   |     | $                     | (1,290,491 | ) |
| Denominators:                                                  |     |                                     |            |   |     |                       |            |   |     |                                     |            |   |     |                       |            |   |
| Weighted-average shares outstanding                            |     |                                     |  2,722,627 |   |     |                       |  2,572,500 |   |     |                                     |  7,416,033 |   |     |                       |  2,572,500 |   |
| Basic and diluted net income/ (loss) per share                 |     | $                                   |       0.32 |   |     | $                     |      (0.40 | ) |     | $                                   |       0.26 |   |     | $                     |      (0.50 | ) |

**Income Taxes**

The Company accounts for income taxes under FASB ASC 740, “Income Taxes” (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived

F-24

from tax loss and